

CLAIMS

This listing of the claims will replace all prior versions of the claims.

1. (Currently amended) A method of attenuating the transmission or infection of an immunodeficiency virus into a cell comprising providing to said cell an inhibitor of p21, wherein said inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least about 50% in said transmission or infection of said virus relative to an untreated cell, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.

2. (Original) The method of claim 1, wherein said immunodeficiency virus is human immunodeficiency virus (HIV), and said cell is a human cell.

3. (Withdrawn) The method of claim 1, wherein said inhibitor of p21 is a polynucleotide.

4. (Withdrawn) The method of claim 2, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.

5. (Withdrawn) The method of claim 3, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.

6. (Withdrawn) The method of claim 5, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:4.

7. (Withdrawn) The method of claim 6, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:8 or SEQ ID NO.:10.

8. (Withdrawn) The method of claim 3, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.

9. (Withdrawn) The method of claim 8, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:6.

10. (Withdrawn) The method of claim 9, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:7 or SEQ ID NO.:9.

11. (Withdrawn) The method of claim 1, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.

12. (Cancelled)

13. (Currently amended) A method of treating AIDS in an individual, comprising providing to HIV-1 infected cells of said individual, or to HIV-1 susceptible cells of such individual, an amount of a p21 inhibitor sufficient to attenuate the propagation of HIV, wherein said inhibitor is provided in an amount and duration sufficient to cause an attenuation of at least 50% in said propagation of HIV relative to untreated cells, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.

14. (Withdrawn) The method of claim 10, wherein said inhibitor of p21 is a polynucleotide.

15. (Withdrawn) The method of claim 11, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.

16. (Withdrawn) The method of claim 11, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.

17. (Withdrawn) The method of claim 16, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:4.

18. (Withdrawn) The method of claim 17, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:8 or SEQ ID NO.:10.

19. (Withdrawn) The method of claim 11, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.

20. (Withdrawn) The method of claim 19, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:6.

21. (Withdrawn) The method of claim 20, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:7 or SEQ ID NO.:9.

22. (Withdrawn) The method of claim 13, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.

23. (Cancelled)

24. (Withdrawn) A pharmaceutical composition comprising an inhibitor of p21 and an excipient or carrier, wherein said inhibitor is present in an amount sufficient to attenuate the propagation of HIV, wherein said inhibitor is present in said composition in an amount sufficient to cause an attenuation of at least 50% in said propagation of HIV relative to untreated cells.

25. (Withdrawn) The composition of claim 24, wherein said inhibitor of p21 is a polynucleotide.

26. (Withdrawn) The composition of claim 25, wherein said polynucleotide is complementary to a portion of a p21 gene or p21 cDNA molecule.

27. (Withdrawn) The composition of claim 25, wherein said p21 gene or p21 cDNA is of a human p21 gene or p21 cDNA molecule.

28. (Withdrawn) The composition of claim 27, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:4.

29. (Withdrawn) The composition of claim 28, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:8 or SEQ ID NO.:10.

30. (Withdrawn) The composition of claim 25, wherein said p21 gene or p21 cDNA is of a non-human animal or is a variant of a non-human p21 gene or p21 cDNA molecule.

31. (Withdrawn) The composition of claim 30, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:6.

32. (Withdrawn) The composition of claim 31, wherein said polynucleotide comprises at least 10 contiguous nucleotides of SEQ ID NO.:7 or SEQ ID NO.:9.

33. (Withdrawn) The composition of claim 24, wherein said inhibitor of p21 is a protein or organic molecule other than a polynucleotide.

34. (Withdrawn) The composition of claim 33, wherein said inhibitor is 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), or a salt or derivative thereof.